Centering discussion on a patient profile of HER2+ gastric cancer, experts in oncology discuss the occurrence of neutropenia with trastuzumab deruxtecan therapy.
Informing Patients With Cancer About the Potential Impact of Immunotherapy on Pregnancy
An expert explores the complexities of immunotherapy during pregnancy, highlighting risks to the fetus and the crucial role of oncology nurses in patient education and management.
ctDNA Monitoring is a Piece of the Puzzle in CRC Treatment
Holly Chitwood, DNP, FNP-C, AGACNP-BC, explains how circulating tumor DNA monitoring helps providers screen minimal residual disease in individuals with colorectal cancer.
ASCO Updates Guidance on CDK4/6 Inhibitors in Adjuvant Setting for HR+, HER2- Early Breast Cancer
This recommendation is an update to the 2020 ASCO guideline on optimal adjuvant chemotherapy and targeted therapy for the treatment of breast cancer.
Improving The Rate Of Accurate Inflammatory Breast Cancer Diagnoses
Ryan Tamargo, NP, AONCP, discusses the launch of an online inflammatory breast cancer scoring system tool.
Celecoxib Plus Adjuvant Chemo Provides Survival Benefit for PIK3CA-Mutated Stage III Colon Cancer
Disease-free survival and overall survival improved with celecoxib plus advanced chemotherapy in patients with PIK3CA-mutated stage III colon cancer.
Tailoring Second-Line Treatments for HR-Positive, HER2-Negative Metastatic Breast Cancer
With several options available for the second-line treatment of HR-positive, HER2-negative mBC, an expert emphasized the importance of tailoring treatment for every patient.
Pembrolizumab Plus Chemo Improves Overall Survival in Resectable Gastric Cancer
Ibrutinib-Venetoclax Combo Elicits Durable Complete Responses in TP53+ MCL
Brentuximab Vedotin Triplet Provides Stronger Survival Signal vs R2 in R/R DLBCL
Durvalumab Plus Chemo Shows Sustained Survival Benefit in Advanced Biliary Tract Cancer